Donepezil Hydrochloride Tablet
Product Images NDC 68788-8711

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 68788-8711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Donepezil HCl Tablets 5mg (5mg 30s)

Donepezil HCl Tablets 5mg (5mg 30s)
Label for Donepezil HCl Tablets 5 mg, a film-coated oral tablet generic for Aricept. The label shows the strength as 5 mg donepezil HCl USP, manufactured by ACI HealthCare Limited, with storage instructions for temperature and child safety warnings. The label includes bilingual directions for use in English and Spanish and displays the Preferred Pharmaceuticals Inc. logo.*
FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
Line chart showing the mean change from baseline in ADAS-cog scores over 30 weeks of drug treatment. Three groups are compared: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The vertical axis indicates clinical improvement or decline, while the horizontal axis shows weeks of treatment. Error bars represent standard error.*
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
A cumulative percentage curve graph comparing patients treated with Donepezil Hydrochloride 10 mg/day and placebo, showing ADCS-ADL change from baseline on the horizontal axis and cumulative percentage of patients on the vertical axis.*
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
A line graph depicting the SIB change from baseline over 24 weeks of drug treatment for Donepezil Hydrochloride at 23 mg/day and 10 mg/day. The y-axis shows the LS mean change with standard error, indicating clinical improvement or decline, while the x-axis represents weeks of drug treatment. The 23 mg/day dose shows greater clinical improvement than the 10 mg/day dose over time.*
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
A cumulative percentage of patients line graph showing changes in SIB (Severe Impairment Battery) scores from baseline for two Donepezil Hydrochloride dosing groups, 23 mg/day and 10 mg/day. The x-axis represents SIB change from baseline, ranging from +50 to -60, and the y-axis shows the cumulative percentage of patients from 0 to 100%.*
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
A bar chart displays the percentage of patients rated by CIBIC-plus scale categories after treatment with Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. Categories range from "Markedly Improved" to "Markedly Worse," showing most patients experienced "No Change" or minimal differences.*
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
A cumulative percentage plot showing patient response comparing Placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg treatment groups. The x-axis represents change from baseline on the ADAS-cog scale, while the y-axis shows the cumulative percentage of patients. A table of treatment group percentages at various change points (-7, -4, 0) is included.*
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
A bar chart displaying CIBIC-plus ratings for patients receiving Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis shows categories from Markedly Improved to Markedly Worse, while the y-axis represents the percentage of patients. The chart compares patient outcomes across the three groups.*
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
A line graph showing changes from baseline in ADAS-cog scores over 15 weeks of drug treatment, comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The graph illustrates clinical improvement or decline over time, with markers and error bars representing mean changes and standard error.*
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
A cumulative percentage plot showing the change from baseline in cognitive scores for patients treated with Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo. The x-axis represents the change from baseline, and the y-axis shows the cumulative percentage of patients. The graph includes vertical reference lines at 7 points, 4 points, and no change. A table below the graph summarizes the percentage of patients in each treatment group experiencing changes of -7, -4, and 0 points on the ADAS-cog scale.*
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
Bar chart showing the distribution of patient responses based on the CIBIC-plus Rating for Donepezil Hydrochloride at dosages of 5 mg/day and 10 mg/day compared to placebo. The chart displays percentages of patients across categories from 'Markedly Improved' to 'Markedly Worse.'*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
A line graph depicting SIB (Severe Impairment Battery) change from baseline (mean ± SE) over 6 months of drug treatment. Two lines compare Donepezil Hydrochloride 10 mg/day and placebo, showing clinical improvement and decline relative to baseline on the vertical axis labeled accordingly.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
A cumulative percentage graph comparing Donepezil Hydrochloride 10 mg/day with placebo. The x-axis shows SIB (Severe Impairment Battery) change from baseline, and the y-axis represents the cumulative percentage of patients. Two curves illustrate patient response distributions for the drug and placebo groups.*
FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
A line graph depicting mean change from baseline in ADCS-ADL scores over six months of drug treatment. The x-axis shows months of treatment (0, 3, 6) and the y-axis shows mean change from baseline. Two lines represent Donepezil Hydrochloride 10 mg/day and placebo, with Donepezil showing less decline in scores compared to placebo. Vertical error bars indicate standard error. Clinical improvement is labeled above baseline and clinical decline below.*
FDA Label Image

Chemical Structure (Donepezil Str)

Chemical Structure (Donepezil Str)
Chemical structure of Donepezil Hydrochloride, showing its molecular framework including aromatic rings and functional groups associated with the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.